Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

This study is testing whether a diabetes drug called erugliflozin (an SGLT2 inhibitor) can reduce liver fat and liver scarring (fibrosis) in people with Type 2 diabetes who also have fatty liver disease (NASH or NAFLD), while also improving blood sugar control. **You may be eligible if...** - You are between 18 and 65 years old - You have Type 2 diabetes with an HbA1c between 6.5% and 10% - You have a BMI above 23 kg/m² - You have fatty liver disease confirmed by ultrasound - You have not previously used SGLT2 inhibitors or insulin **You may NOT be eligible if...** - You have used SGLT2 inhibitors, GLP-1 medications, or insulin in the past 3 months - You have used pioglitazone in the past 6 months - You have had bariatric (weight loss) surgery or used weight loss medications recently - You have uncontrolled thyroid disease, serious kidney disease, or Type 1 diabetes Talk to your doctor to see if this trial is right for you.